REGENXBIO Inc. (Nasdaq: RGNX) today announced it will initiate a pivotal Phase IIb/III clinical trial for investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) ...

In patients with diabetic macular edema in both eyes, the port delivery system in one eye achieves a superior anatomical ...

With an increased focus on proactive care, Intermountain Health has made significant strides in the past year to expand ...

An intravitreal implant shows promise in enhancing visual function and retinal structure in diabetic retinopathy patients, according to recent research.

PER-001, delivered through a slow-release, dissolvable implant in the vitreous cavity of the eye, is designed to block ...

Diabetic retinopathy remains a major cause of vision loss among working-age individuals worldwide. While chronic ...

In a separate study, an implant containing a different investigational endothelin antagonist (PER-001) reduced macular ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The prevalence of cataract, responsible for 66.2% of blindness cases, and the silent rise of glaucoma (affecting 12 million ...

Results confirm previous findings that nonarteritic anterior ischemic optic neuropathy (NAION) was more likely in those who used semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA).

A new study published in the Nature Scientific Reports showed that compared to kidney recipients who got preemptive transplants, individuals who experienced dialysis prior to transplantation are ...

From eye fatigue to headaches, you may be missing signs your eye power has changed, mistaking them as stress, exhaustion or something else.